Vitamin D Therapy - Global Strategic Business Report

Global Vitamin D Therapy Market to Reach $7.7 Billion by 2030

The global market for Vitamin D Therapy estimated at US$2.5 Billion in the year 2022, is projected to reach a revised size of US$7.7 Billion by 2030, growing at a CAGR of 15% over the analysis period 2022-2030. Oral, one of the segments analyzed in the report, is projected to record 15.5% CAGR and reach US$5.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Parenteral segment is readjusted to a revised 14% CAGR for the next 8-year period.

The U.S. Market is Estimated at $734.1 Million, While China is Forecast to Grow at 14.3% CAGR

The Vitamin D Therapy market in the U.S. is estimated at US$734.1 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 14.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13% and 12.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.

Select Competitors (Total 36 Featured) -

• Abbott
• Alkem Laboratories Ltd.
• Cadila Healthcare Ltd.
• GlaxoSmithKline PLC
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year